Dermovate (clobetasol, topical): Uses, Dosage & Side Effects

What it's for (Indications)

Clobetasol topical is indicated for the short-term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses.
These conditions include, but are not limited to, severe plaque psoriasis, recalcitrant eczemas (e.
g.
, atopic dermatitis, nummular eczema), lichen planus, discoid lupus erythematosus, and other dermatoses where a potent corticosteroid is deemed necessary due to the severity or unresponsiveness to less potent agents.
Its potent anti-inflammatory and immunosuppressive properties are utilized to alleviate symptoms such as erythema, scaling, and itching, particularly in cases where rapid and effective suppression of inflammation is required.
The use of clobetasol should always be under the guidance of a healthcare professional due to its high potency.

Dosage Information

Type	Guideline
Standard	Clobetasol topical is typically applied as a thin layer to the affected skin areas once or twice daily, depending on the formulation (e.g., cream, ointment, gel, foam, solution) and the severity of the condition. Treatment should generally be limited to two consecutive weeks, and the total dosage applied should not exceed 50 grams per week. For certain specific conditions or formulations, the recommended duration and frequency may vary, but strict adherence to prescribing information is crucial. Application should be gentle, ensuring complete coverage of the lesion, but without excessive rubbing. Occlusive dressings are generally not recommended due to significantly increased systemic absorption and enhanced risk of adverse effects. Its use in pediatric patients, especially those under 12 years of age, is generally not recommended unless specifically indicated and under strict medical supervision due to their increased susceptibility to systemic toxicity.

Type

Guideline

Standard

Clobetasol topical is typically applied as a thin layer to the affected skin areas once or twice daily, depending on the formulation (e.g., cream, ointment, gel, foam, solution) and the severity of the condition. Treatment should generally be limited to two consecutive weeks, and the total dosage applied should not exceed 50 grams per week. For certain specific conditions or formulations, the recommended duration and frequency may vary, but strict adherence to prescribing information is crucial. Application should be gentle, ensuring complete coverage of the lesion, but without excessive rubbing. Occlusive dressings are generally not recommended due to significantly increased systemic absorption and enhanced risk of adverse effects. Its use in pediatric patients, especially those under 12 years of age, is generally not recommended unless specifically indicated and under strict medical supervision due to their increased susceptibility to systemic toxicity.

Safety & Warnings

Common Side Effects

The most common adverse effects associated with topical clobetasol are localized reactions at the application site, including burning, stinging, itching, irritation, erythema, and dryness.
Prolonged use or application to sensitive areas can lead to significant skin changes such as atrophy, thinning of the skin (striae), telangiectasia, purpura, hypertrichosis, hypopigmentation, and acneiform eruptions.
Folliculitis, allergic contact dermatitis, and perioral dermatitis may also occur.
Systemic adverse effects, although less common with appropriate topical use, can arise due to significant absorption, particularly with extensive application, prolonged duration, or occlusive dressings.
These include hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.
Ophthalmic effects such as cataracts and glaucoma have been reported with periorbital application or high systemic absorption.
Children are particularly susceptible to systemic side effects due to a larger skin surface area to body weight ratio.

Serious Warnings

Black Box Warning: **Serious Warnings: Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression and Cushing's Syndrome Risk** Although clobetasol propionate is for topical use, it is a highly potent corticosteroid with significant potential for systemic absorption. This absorption can lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, particularly when applied over large surface areas, under occlusive dressings, or for prolonged durations. Manifestations of HPA axis suppression, including adrenal insufficiency, may necessitate supplemental systemic corticosteroids. Patients, especially children, are at increased risk due to their larger skin surface area to body weight ratio. Prolonged or extensive use may also result in clinical manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients should be evaluated periodically for evidence of HPA axis suppression. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, reduce the frequency of application, or substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation, but some individuals may require gradual withdrawal to prevent acute adrenal insufficiency.
Clobetasol topical is a highly potent corticosteroid, and caution must be exercised to minimize systemic absorption, which can lead to hypothalamic-pituitary-adrenal (HPA) axis suppression.
Patients, especially children, with extensive application, prolonged use, or occlusive dressings, are at increased risk.
Regular monitoring for signs of HPA axis suppression (e.
g.
, morning plasma cortisol, ACTH stimulation test) may be necessary.
Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can occur.
Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and are thus more susceptible to systemic toxicity.
Long-term use can lead to local skin atrophy, striae, telangiectasia, and irreversible skin damage.
Discontinuation after prolonged use should be gradual to avoid rebound flare-ups.
Clobetasol is not for ophthalmic use and contact with eyes should be avoided due to the risk of glaucoma and cataracts.
It can mask or exacerbate existing skin infections; therefore, concomitant antimicrobial therapy should be considered if an infection is present.

How it Works (Mechanism of Action)

Clobetasol propionate is a synthetic, highly potent corticosteroid primarily characterized by its profound anti-inflammatory, antipruritic, and vasoconstrictive actions. Its mechanism of action involves the induction of phospholipase A2 inhibitory proteins, collectively known as lipocortins. These proteins mediate the inhibition of arachidonic acid release, which is a crucial precursor in the biosynthesis of potent mediators of inflammation, including prostaglandins and leukotrienes. By inhibiting these inflammatory cascades, clobetasol effectively reduces erythema, edema, and pruritus associated with various dermatological conditions. Furthermore, corticosteroids are known to suppress the immune response by inhibiting the proliferation of lymphocytes, reducing the function of macrophages, and stabilizing lysosomal membranes, thereby dampening the overall inflammatory and immunological reactions in the skin. The high potency of clobetasol results from its unique chemical structure, which enhances its affinity for glucocorticoid receptors and prolongs its duration of action.